These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 35068786)

  • 1. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
    Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
    J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
    Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Mitra A
    Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.
    Padole P; Arora A; Sharma P; Chand P; Verma N; Kumar A
    J Clin Exp Hepatol; 2022; 12(2):435-439. PubMed ID: 35535066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
    Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
    Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
    Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Case Series of Decrease in Shear Wave Elastography Values in Ten Diabetic Dyslipidemia Patients Having NAFLD with Saroglitazar 4 mg: An Indian Experience.
    Roy S
    Case Rep Med; 2020; 2020():4287075. PubMed ID: 32280349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL.
    Mir BA; Sharma B; Sharma R; Bodh V; Chauhan A; Majeed T; Haq I; Sharma N; Sharma D
    J Clin Exp Hepatol; 2024; 14(5):101398. PubMed ID: 38628977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
    Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
    Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Bandyopadhyay S; Samajdar SS; Das S
    Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102174. PubMed ID: 37380128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
    Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience.
    Chaudhuri S; Dutta A; Chakraborty SBD
    JGH Open; 2023 Mar; 7(3):215-220. PubMed ID: 36968568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
    Joshi SR
    Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).
    Duseja A; Singh SP; De A; Madan K; Rao PN; Shukla A; Choudhuri G; Saigal S; Shalimar ; Arora A; Anand AC; Das A; Kumar A; Eapen CE; Devadas K; Shenoy KT; Panigrahi M; Wadhawan M; Rathi M; Kumar M; Choudhary NS; Saraf N; Nath P; Kar S; Alam S; Shah S; Nijhawan S; Acharya SK; Aggarwal V; Saraswat VA; Chawla YK
    J Clin Exp Hepatol; 2023; 13(2):273-302. PubMed ID: 36950481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Ferritin level, microalbuminuria and non-alcoholic fatty liver disease in type 2 diabetic patients.
    Amin RF; El Bendary AS; Ezzat SE; Mohamed WS
    Diabetes Metab Syndr; 2019; 13(3):2226-2229. PubMed ID: 31235161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
    Garvey WT; Mechanick JI; Brett EM; Garber AJ; Hurley DL; Jastreboff AM; Nadolsky K; Pessah-Pollack R; Plodkowski R;
    Endocr Pract; 2016 Jul; 22 Suppl 3():1-203. PubMed ID: 27219496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).
    Pai V; Paneerselvam A; Mukhopadhyay S; Bhansali A; Kamath D; Shankar V; Gambhire D; Jani RH; Joshi S; Patel P
    J Diabetes Sci Technol; 2014 Jan; 8(1):132-141. PubMed ID: 24876549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.